Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
64Cu-NOTA-FVIIai is a radiopharmaceutical PET imaging tracer designed to target and visualize tissue factor (TF) expression in tumors, particularly pancreatic adenocarcinoma. It consists of active site-inhibited coagulation factor VII (FVIIai), which serves as the natural ligand for TF, conjugated to the chelator 2-S-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid (p-SCN-Bn-NOTA) and radiolabeled with the positron emitter copper-64 (64Cu). By utilizing an active site-inhibited version of FVII, the tracer retains high binding affinity for TF without triggering the coagulation cascade. It is being developed as a potential companion diagnostic to identify patients with high TF expression who may benefit from TF-targeted cancer therapies, as TF levels often correlate with advanced stage and poor survival in pancreatic cancer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 64Cu-NOTA-FVIIai.